| 2026-08-04 | Press release | Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in |
| 2026-08-04 | Press release | Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader |
| 2026-07-21 | Press release | Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potenti |
| 2026-07-09 | Press release | Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-07-09 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-09 | 10-Q | Form 10-Q for the quarter ended May 31 |
| 2026-06-11 | Press release | Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in |
| 2026-06-11 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-08 | Press release | Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class |
| 2026-06-08 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-15 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-14 | Press release | Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic |
| 2026-05-14 | Deck | BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria |
| 2026-05-13 | Press release | Nurix Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-05-12 | Press release | Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress |
| 2026-04-22 | Press release | Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR |
| 2026-04-22 | Deck | Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth |
| 2026-04-21 | Deck | NRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma |
| 2026-04-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-08 | 10-Q | Form 10-Q for the quarter ended Feb 28 |
| 2026-03-27 | Proxy | Definitive proxy statement |
| 2026-03-24 | Deck | Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation |
| 2026-03-06 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-28 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-12 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-12 | Deck | Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study |
| 2025-12-09 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-08 | Deck | Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial |
| 2025-12-07 | Deck | Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation |
| 2025-11-10 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-07 | Deck | NX-1607: Translational Insights From a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors |
| 2025-10-24 | Transcript | FY25 earnings call transcript |
| 2025-10-22 | 8-K | Form 8-K, Item 7.01 |
| 2025-10-22 | 8-K | Form 8-K, Item 8.01 |
| 2025-10-09 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-09 | 10-Q | Form 10-Q for the quarter ended Aug 31 |
| 2025-09-03 | 8-K | Form 8-K, Item 7.01 |
| 2025-08-22 | 8-K | Form 8-K, Item 5.02 |
| 2025-07-09 | 8-K | Form 8-K, Item 2.02 results |